Navigation Links
Nonclinical in Medical News

Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research

Nonclinical Studies Demonstrate that SNS-595 Acts through a Dual Mechanism and May Evade Common Drug Resistance Mechanisms Research Supports Current Clinical Development of SNS-595 in AML and Ovarian Cancer and Potential in Additional Indications SOUTH SAN FRANCISCO, Calif.,...

InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting

...while mitigating the typical side effect profile." "Translation of the nonclinical profile of INT131 into the clinic is an exciting validation of the selectiv... lowering in rodent models of T2DM, while also showing remarkable safety in nonclinical studies of INT131 even at multiples of clinical exposures that far exceed t...

Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit

...tics and from Alnylam Pharmaceuticals. QPI-1007, a siRNA that utilizes a proprietary structure developed by Quark, is being evaluated in IND-enabling nonclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates based on internally developed n...

Ceregene Presents Additional Clinical Data from Phase 2 Trial of CERE-120 for Parkinson's Disease

...leted enrollment of 58 patients with advanced Parkinson's disease in October 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in t...

Sunesis Reports Financial Results for the First Quarter 2009

...) Annual Meeting in Denver, Colorado. Results from nonclinical translational research studies identified potent v...e tranched financing, the activity of voreloxin in nonclinical studies, planned additional clinical testing and d... of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the re...

CuraGen Reports First Quarter 2009 Financial Results

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical c...

Health Insurers to Make Major Investment in Primary Care, Patients and Physicians to Benefit

...who serves on the initiative's advisory board. "Physicians will be able to focus more on the cognitive aspects of patient care, delegating some of the nonclinical work to their staff. There is good evidence that patients' quality of life will be significantly improved as a result." Creating a Medical Home ...

PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil

... his long-term role as MPA Team Leader. During his tenure at MPA Dr. Neil assessed marketing authorizations and clinical trial applications, including nonclinical and pharmacology aspects of more than 1,000 applications spanning all stages of development and therapeutic areas. He has served as an expert to the E...

AMA Foundation Honors Outstanding Leaders in Medicine

...Awards. Presented in association with Pfizer Inc, this award recognizes medical students, residents and fellows and early career physicians for their nonclinical leadership skills in organized medicine, education, public health or community service. The Leadership Awards are part of the AMA Foundation's Excell...

Covance Reports Fourth Quarter and Full-Year 2008 Results

... $205.4 $195.9 4.8% Margin % 21.4% 24.8% 24.3% 25.2% The Company's Early Development segment includes nonclinical toxicology, analytical chemistry, clinical pharmacology services, and research products. Early Development net revenues for the fourth quarter of 2008...
Nonclinical in Medical Technology

Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research

SNS-032 Demonstrates Activity in Multiple Myeloma and Mantle Cell Lymphoma SOUTH SAN FRANCISCO, Calif., April 16 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ) today reported data from nonclinical studies of SNS-032 in multiple myeloma and mantle cell lymphoma. Data fr...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

Samaritan Announces Positive Data in Nonclinical (IND) In- Vitro Studies for Promising Alzheimer's Drug LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- Samaritan Pharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs, is pleased to announce positive results were attained with its late-stage p...

CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical c...

CuraGen Updates CR011-vcMMAE Data at ASCO

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical c...

CuraGen to Present CR011-vcMMAE Data at ASCO

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical c...

Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity

...d posed by this very problematic gram-negative pathogen, which is a common cause of serious infection associated with high morbidity and mortality. nonclinical studies have shown CXA-101 is highly active against multiple drug-resistant Pseudomonas aeruginosa, including many strains resistant to carbapenems,...

InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study

...n's President and CEO, Denny Lanfear. "We anticipate having results from INT131-007 in the second half of this year concurrent with completion of all nonclinical and CMC efforts, enabling initiation of the INT131 Phase 3 program in 1H2010." INT131 is a selective PPAR gamma modulator which has consistently ...

Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans

...rchers presented the expanded data, as well as new nonclinical data from the company's RapidResponse(TM) DNA vacc... vaccine Phase 1 clinical trial and the results of nonclinical mouse studies of Vaxfectin(R)-formulated influenza...sults will be confirmed in larger studies; whether nonclinical results from mouse studies will advance to human c...

CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, as well as risk associated with the success of competing products and technologies, CuraGen's stage of deve...

Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months

...today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin(R)...DNA vaccine Phase 1 clinical trial, the results of nonclinical mouse studies of Vaxfectin(R)-formulated protein-based influenza vaccines, and the results of a nonclinical mouse study of a Vaxfectin(R)-formulated TRP-2 pep...
Nonclinical in Medical Products

Landmarx ENT Image Guidance System

Description:...ndmarx ENT image guidance system offers the Zone, a graphical illustration of submillimetric accuracy (Submillimetric accuracy has been established in nonclinical testing) - far more informative than a simple numerical value. It is simple to set up, intutive and easily mastered. It offers real-time and freeze-fr...
Company:Medtronic Xomed, Inc.
Nonclinical in Biological News

OHSU turns innovations into commercial opportunities at record pace

...panies based on OHSU discoveries were incorporated during the year, bringing the total to 33 since 2000 and 64 since the early 1970s. Sixty-three nonclinical research agreements totaling $6.7 million, up 37 percent from 4.9 million in the previous year. Income from commercialization of inventions licen...

Brain differences could explain why males and females experience pain relief differently

... that opioid drugs or "narcotics", such as morphine, are essential in the management of chronic pain. However, there is well-established clinical and nonclinical evidence that males and females do not respond the same to the effects of morphine. Specifically, females tend to require higher doses of morphine th...
Nonclinical in Biological Technology

Emisphere Technologies, Inc. Appoints Gary Riley as Vice President Nonclinical Development & Applied Biology

TARRYTOWN, N.Y., Oct. 24 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS ) today announced that Gary Riley has been appointed to the position of Vice President, Nonclinical Development and Applied Biology, effective November 6, 2007. Dr. Riley will be responsible for the ...

CuraGen Reports Second Quarter 2009 Financial Results

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources; the success of competing products and technologies; CuraGen's stage of development as a biopharmaceutical c...

Sunesis Reports Financial Results for the Second Quarter 2009

...xin, the completion of the tranched financing, the activity of voreloxin in nonclinical studies, planned additional enrollment, clinical testing and development ef...nds may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the requirements of the FDA or ...

Calvert Research and CureDM Sign Collaborative Agreement

...ut Calvert Labs, Inc. Regarded by many as the premier IND-enabling contract research organization, Calvert Laboratories has been providing contract nonclinical services for almost four decades. As a global service provider, Calvert Labs' core offerings include toxicology (acute through chronic & carcinog...

CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical c...

Calvert Labs Announces the Hiring of Terry Ladd

... About Calvert Labs: Regarded by many as the premier IND-enabling contract research organization, Calvert Laboratories has been providing contract nonclinical services for almost four decades. As a global service provider, Calvert Labs' core offerings include toxicology (acute through chronic & carcinog...

NexBio to Present at 2009 Biotech Showcase

... effectively inhibits numerous strains of influenza and parainfluenza virus nonclinical models. Unlike current antiviral compounds and vaccines, Fludase(R) target...ce compared with currently available antiviral drugs. Extensive, prolonged nonclinical studies have not shown the development of any meaningful resistance. ...

Ceregene Announces Clinical Data From Phase 2 Clinical Trial of CERE-120 for Parkinson's Disease

...eted enrollment of 58 patients with advanced Parkinson's disease in November 2007. This study was launched after successful execution of an extensive nonclinical program and preliminary evidence of safety and efficacy in advanced Parkinson's patients via an open-label Phase 1 trial in 12 patients. Patients in t...

CuraGen Reports Third Quarter 2008 Financial Results

...grams will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, as well as risk associated with the success of competing products and technologies, CuraGen's stage of deve...

Ground Zero Pharmaceuticals Announces Expansion of Regulatory and Product Development Consulting Services

...regulatory representation and submissions (paper and electronic), strategic medical consulting, preclinical planning, auditing and review of clinical, nonclinical and CMO sites, medical writing, chemistry, manufacturing and controls consulting, clinical assessment, data management, biostatics, and project manage...
Nonclinical in Biological Dictionary

Hybridoma

...ouse hybridoma development. ... Home > Drug Development Services > nonclinical > Antibody Services > Hybridoma Development ... Standard procedu...r rat hybridoma development. ... Home > Drug Development Services > nonclinical > Antibody Services > Hybridoma Development ... This technology ...
Other Tags
(Date:12/25/2014)... (PRWEB) December 26, 2014 The report ... 2023” focuses on the current treatment landscape, unmet needs, ... market. TS-1 is an anti-cancer drug which is typically ... and is also used for treating gastric cancer and ... otastat potassium. The drug was first approved in 1999 ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... Dennis Thompson HealthDay ... Researchers could be closing in on a "fountain of youth" ... the health of older adults, a new study suggests. ... given a drug that targets a genetic signaling pathway linked ... Novartis report. The experimental medication, a version ...
(Date:12/25/2014)... North Carolina (PRWEB) December 25, 2014 ... North Carolina Retirement Community, recently showed their generous ... girls of the Catawba County Parenting Network- Grandparents ... the 10 children gathered around the largest Christmas ... to open presents purchased by residents of the ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Retirement Community Residents Make Impact During Holiday Season 2
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
Other Contents